NSC745885 manufacturers
- NSC745885
-
- $239.00 / 5mg
-
2024-10-24
- CAS:4219-52-7
- Min. Order:
- Purity:
- Supply Ability: 10g
- NSC745885
-
- $20.00 / 1KG
-
2024-08-11
- CAS:4219-52-7
- Min. Order: 1KG
- Purity: 99%
- Supply Ability: 200000KG
|
| | NSC745885 Basic information |
| Product Name: | NSC745885 | | Synonyms: | NSC745885;NSC-745885,NSC745885;Anthra[1,2-c][1,2,5]thiadiazole-6,11-dione | | CAS: | 4219-52-7 | | MF: | C14H6N2O2S | | MW: | 266.27 | | EINECS: | | | Product Categories: | | | Mol File: | 4219-52-7.mol |  |
| | NSC745885 Chemical Properties |
| Boiling point | 470.0±14.0 °C(Predicted) | | density | 1.574±0.06 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO: < 1 mg/mL (insoluble or slightly soluble) *NSC745885 is usually formulated as a suspension. | | form | Solid | | pka | -1.90±0.20(Predicted) | | color | Light yellow to yellow |
| | NSC745885 Usage And Synthesis |
| Uses | NSC745885 an effective anti-tumor agent, shows selective toxicity against multiple cancer cell lines but not normal cells. NSC745885 is an effective down-regulator of EZH2 via proteasome-mediated degradation. NSC745885 provides possibilities for the study of advanced bladder and oral squamous cell carcinoma (OSCC) cancers[1][2]. | | in vivo | NSC745885 (intraperitoneal injection; 2 mg/kg; once daily; 10 days) treatment significantly reduces tumor size when compared with the vehicle control, and exhibits a higher safety than doxorubicin[1]. | Animal Model: | Eight-week-old NOD/SCID (NOD.CB17 Prkdcscid/J) mice[1] | | Dosage: | 2 mg/kg | | Administration: | Intraperitoneal injection; 2 mg/kg; once daily; 10 days | | Result: | Inhibited engrafted tumors growth in vivo. |
| | IC 50 | EZH2 | | References | [1] Chen YW, et al.A novel compound NSC745885 exerts an anti-tumor effect on tongue cancer SAS cells in vitro and in vivo.PLoS One.?2014 Aug 15;9(8):e104703. DOI:10.1371/journal.pone.0104703
[2] Tang SH, et al. Pharmacologic?down-regulation?of?EZH2?suppresses?bladder?cancer?in?vitro?and in?vivo.Oncotarget.?2014 Nov 15;5(21):10342-55. DOI:10.18632/oncotarget.1867 |
| | NSC745885 Preparation Products And Raw materials |
|